Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
ALK negative
i
Other names:
NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
238
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
ALK rearrangement (43)
ALK mutation (20)
ALK wild-type (18)
STRN-ALK rearrangement (10)
ALK translocation (9)
ALK F1174L (7)
ALK G1202R (7)
ALK C1156Y (6)
EGFR wild-type + ALK wild-type (6)
ALK A348D (5)
ALK F856S (5)
EML4-ALK rearrangement (5)
ALK G1202del (4)
ALK G1269A (4)
ALK I1171N (4)
ALK I1171T (4)
ALK rearrangement + TP53 mutation (4)
ALK F1174C (3)
ALK F1174V (3)
ALK F1245C (3)
ALK G1202K (3)
ALK I1171 (3)
ALK L1196M (3)
ALK R1275Q (3)
TYRO3 mutation + ALK mutation (3)
ALK C1156Y + ALK I1171T (2)
ALK C1156Y + ALK L1198F (2)
ALK E1210K (2)
ALK F1174L + ALK G1202R (2)
ALK I1171S (2)
ALK L1152R (2)
ALK L1198F (2)
ALK S1206Y (2)
ALK V1180L (2)
ALK V3a (2)
ALK V3b (2)
DCTN1-ALK rearrangement + ALK-CLIP4 rearrangement (2)
ALK C1156F (1)
ALK C1156Y + ALK G1202R (1)
ALK D1091N (1)
ALK D1203N (1)
ALK E1129V (1)
ALK F1174I (1)
ALK G1123S (1)
ALK G1128A (1)
ALK G1202L (1)
ALK G1202R + ALK F1174L + ALK T1151M (1)
ALK I1268L (1)
ALK L1152R + EGFR mutation (1)
ALK L1152V (1)
ALK L1196M + ALK C1156Y (1)
ALK L1196M + ALK G1202R (1)
ALK L1196M + ALK L1198F (1)
ALK L1198F + ALK G1202R (1)
ALK R1192P (1)
ALK R1209Q (1)
ALK R1231W (1)
ALK R214H (1)
ALK S1157F (1)
ALK T1151M (1)
ALK T1151R (1)
ALK TKD mutation (1)
ALK rearrangement + ALK L1196M + TP53 mutation (1)
ALK rearrangement + ALK R1275Q + TP53 mutation (1)
ALK rearrangement + ALK T1151M + ALK L1198F + EGFR A839V (1)
ALK rearrangement + EGFR D761N + KRAS V14I (1)
ALK rearrangement + HER-2 mutation (1)
ALK rearrangement + KRAS mutation (1)
ALK rearrangement + PIK3CA mutation (1)
ALK rearrangement + TP53 R175H + EGFR A839V + PI3KCA mutation (1)
ALK rearrangement + TP53 wild-type (1)
EGFR L858R + ALK R1275Q (1)
EGFR L858R + ALK rearrangement (1)
EGFR exon 19 deletion + ALK mutation (1)
EGFR mutation + ALK mutation (1)
EGFR wild-type + ALK wild-type + ROS1 wild-type (1)
EGFR wild-type + ALK wild-type + STK11 mutation (1)
EML4-ALK I1171N + EML4-ALK L1196M (1)
EML4-ALK I1171N + EML4-ALK L1196M + EML4-ALK G1202R (1)
LMO7-ALK rearrangement (1)
PLEKHH2-ALK rearrangement (1)
RMST-ALK rearrangement (1)
TP53 G245S + ALK rearrangement (1)
ALK mutation + TP53 mutation (0)
ALK rearrangement (43)
ALK mutation (20)
ALK wild-type (18)
STRN-ALK rearrangement (10)
ALK translocation (9)
ALK F1174L (7)
ALK G1202R (7)
ALK C1156Y (6)
EGFR wild-type + ALK wild-type (6)
ALK A348D (5)
ALK F856S (5)
EML4-ALK rearrangement (5)
ALK G1202del (4)
ALK G1269A (4)
ALK I1171N (4)
ALK I1171T (4)
ALK rearrangement + TP53 mutation (4)
ALK F1174C (3)
ALK F1174V (3)
ALK F1245C (3)
ALK G1202K (3)
ALK I1171 (3)
ALK L1196M (3)
ALK R1275Q (3)
TYRO3 mutation + ALK mutation (3)
ALK C1156Y + ALK I1171T (2)
ALK C1156Y + ALK L1198F (2)
ALK E1210K (2)
ALK F1174L + ALK G1202R (2)
ALK I1171S (2)
ALK L1152R (2)
ALK L1198F (2)
ALK S1206Y (2)
ALK V1180L (2)
ALK V3a (2)
ALK V3b (2)
DCTN1-ALK rearrangement + ALK-CLIP4 rearrangement (2)
ALK C1156F (1)
ALK C1156Y + ALK G1202R (1)
ALK D1091N (1)
ALK D1203N (1)
ALK E1129V (1)
ALK F1174I (1)
ALK G1123S (1)
ALK G1128A (1)
ALK G1202L (1)
ALK G1202R + ALK F1174L + ALK T1151M (1)
ALK I1268L (1)
ALK L1152R + EGFR mutation (1)
ALK L1152V (1)
ALK L1196M + ALK C1156Y (1)
ALK L1196M + ALK G1202R (1)
ALK L1196M + ALK L1198F (1)
ALK L1198F + ALK G1202R (1)
ALK R1192P (1)
ALK R1209Q (1)
ALK R1231W (1)
ALK R214H (1)
ALK S1157F (1)
ALK T1151M (1)
ALK T1151R (1)
ALK TKD mutation (1)
ALK rearrangement + ALK L1196M + TP53 mutation (1)
ALK rearrangement + ALK R1275Q + TP53 mutation (1)
ALK rearrangement + ALK T1151M + ALK L1198F + EGFR A839V (1)
ALK rearrangement + EGFR D761N + KRAS V14I (1)
ALK rearrangement + HER-2 mutation (1)
ALK rearrangement + KRAS mutation (1)
ALK rearrangement + PIK3CA mutation (1)
ALK rearrangement + TP53 R175H + EGFR A839V + PI3KCA mutation (1)
ALK rearrangement + TP53 wild-type (1)
EGFR L858R + ALK R1275Q (1)
EGFR L858R + ALK rearrangement (1)
EGFR exon 19 deletion + ALK mutation (1)
EGFR mutation + ALK mutation (1)
EGFR wild-type + ALK wild-type + ROS1 wild-type (1)
EGFR wild-type + ALK wild-type + STK11 mutation (1)
EML4-ALK I1171N + EML4-ALK L1196M (1)
EML4-ALK I1171N + EML4-ALK L1196M + EML4-ALK G1202R (1)
LMO7-ALK rearrangement (1)
PLEKHH2-ALK rearrangement (1)
RMST-ALK rearrangement (1)
TP53 G245S + ALK rearrangement (1)
ALK mutation + TP53 mutation (0)
›
Associations
(4)
News
Trials
Search handles
@Tony_Calles
@ixazebe
@ns_chd
@timfenske
Search handles
@Tony_Calles
@ixazebe
@ns_chd
@timfenske
Filter by
Latest
1year
ALK-negative anaplastic large cell lymphoma with JAK2 rearrangement mimicking classic Hodgkin lymphoma | Blood | American Society of Hematology https://t.co/r3X6TfGAVp (@ixazebe)
1 year ago
ALK (Anaplastic lymphoma kinase) • JAK2 (Janus kinase 2)
|
ALK negative • JAK2 rearrangement
2years
Great work by @FordePatrick & colleagues. This trial has now established clear role for #immunotherapy in almost all stages of #EGFR/#ALK negative #NSCLC (early-stage neoadjuvant; early-stage adjuvant; locally advanced; metastatic). #PDL1 expression correlated w/ outcomes in all! (@ns_chd)
2 years ago
Clinical • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression • ALK negative
2years
Based on the recent neo-adjuvant data and approval of Chemo-IO (#CM816) for Stage Ib-IIIA NSCLC, EGFR/ALK negative, what would you be doing in your clinical practice? In neo-adj settings, would you offer: #LCSM @FordePatrick @n8pennell @CharuAggarwalMD @JackWestMD @DrJNaidoo (@OncBrothers)
2 years ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
ALK negative
2years
Similar situation now with a 50 yo male former smoker, no other comorbidities. lung adenocarcinoma, EGFR/ALK negative, PD-L1 20%. Stage IIIB (T4N2 by 7th and 8th AJCC Ed) VATS RUL lobectomy after neoadjuvant chemo-IO. pCR Remains NED (cc’d @DoctorJSpicer: again no N2 pics 🙏) (@Tony_Calles)
2 years ago
Clinical
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
|
PD-L1 negative • ALK negative
almost3years
IMPACT OF DUSP22 REARRANGEMENT ON THE PROGNOSIS OF SYSTEMIC ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA: A LYSA AND TENOMIC STUDY. Largest study to date... no impact of DUSP22 rearr on PFS. #16icml https://t.co/JI27UQtgUx (@timfenske)
almost 3 years ago
ALK (Anaplastic lymphoma kinase)
|
ALK negative
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login